Rimegepant 75 mg for 52 weeks is well tolerated, with no liver safety signals and a sustained reduction in monthly migraine days, a new extension study shows.

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Fractyl Health offers a high-risk, high-reward setup with a near-term binary catalyst in the REMAIN-1 cohort data expected Q3 ...

First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients ...

PYPD PolyPid Ltd. (NASDAQ:PYPD) is a late clinical stage biopharma company focused on developing locally administered, prolonged-release therapeutics using its proprietary Polymer-Lipid Encapsulation ...

Eli Lilly is advancing its Phase 2 clinical trial to test LY3841136 for weight management in obese and overweight adults.

Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces that all the 28 participants have recently been dosed in the randomized, double-blind, placebo-controlled study (ASC47-103 study, NCT06972992) ...

BiomX Inc. (AMEX:PHGE) saw its stock jump 60% after announcing the commencement of patient dosing in its Phase 2b clinical ...

Turn Therapeutics today announced the initiation of a randomized, double-blind, vehicle-controlled clinical trial evaluating its topical GX-03 formulation -- previously used in the company's advanced ...

Biodexa Announces Filing of CTA in Europe for Phase 3 Serenta Trial in ...

In patients who transitioned from injected SRLs to once-daily oral PALSONIFY, mean insulin-like growth factor 1 (IGF-1) levels remained stable with IGF-1 (mean ± SE) of 0.93 ± 0.22 at OLE baseline and ...